Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.
Novartis has unveiled Phase III data showing that partnering Kisqali with an endocrine therapy significantly prolonged progression-free survival compared to an endocrine therapy alone in patients with breast cancer.